Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ELAN 
Elanco Animal Health (ELAN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ELAN (3-star) is a STRONG-BUY. BUY since 77 days. Profits (54.26%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $18.18
1 Year Target Price $18.18
| 6 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 69.72% | Avg. Invested days 57 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.17B USD | Price to earnings Ratio 20.97 | 1Y Target Price 18.18 |
Price to earnings Ratio 20.97 | 1Y Target Price 18.18 | ||
Volume (30-day avg) 15 | Beta 1.66 | 52 Weeks Range 8.02 - 18.87 | Updated Date 08/28/2025 |
52 Weeks Range 8.02 - 18.87 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.2 | Actual 0.26 |
Profitability
Profit Margin 9.68% | Operating Margin (TTM) 6.85% |
Management Effectiveness
Return on Assets (TTM) 0.98% | Return on Equity (TTM) 6.83% |
Valuation
Trailing PE 20.97 | Forward PE 22.57 | Enterprise Value 12856085349 | Price to Sales(TTM) 2.04 |
Enterprise Value 12856085349 | Price to Sales(TTM) 2.04 | ||
Enterprise Value to Revenue 2.87 | Enterprise Value to EBITDA 8.87 | Shares Outstanding 496814016 | Shares Floating 492938555 |
Shares Outstanding 496814016 | Shares Floating 492938555 | ||
Percent Insiders 1.03 | Percent Institutions 109.89 |
Upturn AI SWOT
Elanco Animal Health
Company Overview
History and Background
Elanco Animal Health was founded in 1954 as a division of Eli Lilly and Company. It became an independent, publicly traded company in 2019. Elanco focuses on developing and marketing products and services to improve animal health and protein production.
Core Business Areas
- Companion Animal: Focuses on products for pets, including parasiticides, vaccines, and therapeutics.
- Food Animal: Provides solutions for livestock, poultry, and aquaculture, including products to improve animal health, productivity, and sustainability.
- Aqua Health: Focuses on solutions that provide preventative and therapeutic care to a wide range of aquatic animals.
Leadership and Structure
Jeff Simmons serves as the President and CEO. The company operates with a functional organizational structure encompassing R&D, commercial operations, and manufacturing.
Top Products and Market Share
Key Offerings
- Credelio: An oral flea and tick medication for dogs and cats. Competes with NexGard (Boehringer Ingelheim), Bravecto (Merck Animal Health), and Revolution (Zoetis). Elanco reports that their flea/tick products make up 23% of sales. Market share data is fragmented, and varies by region, with estimates placing Credelio's share in specific markets at around 10-15%.
- Interceptor Plus: A broad-spectrum dewormer for dogs, also prevents heartworm disease. Competitors include Heartgard Plus (Boehringer Ingelheim) and Tri-Heart Plus (Merck Animal Health). Elanco reports that their flea/tick/heartworm products make up 23% of sales. Market share data is fragmented.
- Galliprant: A non-steroidal anti-inflammatory drug (NSAID) used to treat osteoarthritis in dogs. Competitors include Rimadyl (Zoetis) and Previcox (Boehringer Ingelheim). Elanco reports that their pain/osteoarthritis products make up 17% of sales. Market share data is fragmented.
Market Dynamics
Industry Overview
The animal health industry is growing, driven by increasing pet ownership, rising demand for animal protein, and greater awareness of animal health and welfare. Consolidation through mergers and acquisitions is prevalent.
Positioning
Elanco is a major player in the animal health industry, with a broad portfolio and global presence. Its competitive advantages include its strong R&D capabilities and established relationships with veterinarians and livestock producers.
Total Addressable Market (TAM)
The global animal health market is projected to reach $75 billion - $85 billion by 2030. Elanco is well-positioned to capture a significant share of this TAM through its diverse product portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global presence
- Strong R&D capabilities
- Established relationships with veterinarians and livestock producers
- Strong commercial capabilities
Weaknesses
- High debt level due to the Bayer Animal Health acquisition
- Integration challenges related to acquisitions
- Dependence on key products
- Exposure to regulatory risks
Opportunities
- Growing demand for animal health products in emerging markets
- Increasing pet ownership globally
- Development of new and innovative animal health technologies
- Expanding into adjacent markets, such as pet insurance and diagnostics
Threats
- Competition from established animal health companies
- Generic competition
- Regulatory changes
- Economic downturns
- Animal disease outbreaks
Competitors and Market Share
Key Competitors
- ZOET
- MRK
- BOEHY
Competitive Landscape
Elanco operates in a competitive market with several large players. Elanco's strengths include its broad portfolio and global presence, while its weaknesses include its high debt level and integration challenges.
Major Acquisitions
Bayer Animal Health
- Year: 2020
- Acquisition Price (USD millions): 6890
- Strategic Rationale: Expanded Elanco's product portfolio, geographic reach, and R&D capabilities.
Growth Trajectory and Initiatives
Historical Growth: Elanco's growth has been driven by both organic sales and acquisitions. The acquisition of Bayer Animal Health significantly expanded the company's portfolio and geographic reach.
Future Projections: Analyst estimates project continued revenue growth, driven by new product launches and expanding market share. Profitability is expected to improve as the company integrates the Bayer Animal Health business and reduces debt.
Recent Initiatives: Recent initiatives include new product launches in the companion animal and food animal segments, as well as investments in R&D and manufacturing capacity.
Summary
Elanco is a major animal health player with a broad portfolio and global reach, significantly enhanced by the Bayer acquisition. However, the large debt incurred due to the acquisition remains a key concern. Successful product launches and continued integration efficiency are crucial for future profitability. Elanco needs to manage debt levels and integrate acquired assets effectively to capitalize on market opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Elanco Animal Health Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary by region and product category.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elanco Animal Health
Exchange NYSE | Headquaters Greenfield, IN, United States | ||
IPO Launch date 2018-09-20 | President, CEO & Director Mr. Jeffrey N. Simmons | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9000 | Website https://www.elanco.com |
Full time employees 9000 | Website https://www.elanco.com | ||
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.